Related Experiment Video
Updated: Jun 4, 2026

Mouse Footpad Inoculation Model to Study Viral-Induced Neuroinflammatory Responses
Published on: June 14, 2020
Neurovirulence safety testing of mumps vaccines--historical perspective and current status
1Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, MD 20892, USA. steven.rubin@fda.hhs.gov
Abstract:
Many live, attenuated viral vaccines are derived from wild type viruses with known neurovirulent properties. To assure the absence of residual neurotoxicity, pre-clinical neurovirulence safety testing of candidate vaccines is performed. For mumps virus, a highly neurotropic virus, neurovirulence safety testing is performed in monkeys. However, laboratory studies suggest an inability of this test to correctly discern among virus strains of varying neurovirulence potential in man, and, further, some vaccines found to be neuroattenuated in monkeys were later found to be neurovirulent in humans when administered in large numbers. Over the past decade, concerted efforts have been made to replace monkey-based neurovirulence safety testing with more informative, alternative methods. This review summarizes the current status of mumps vaccine neurovirulence safety testing and insights into models currently approved and those under development.
Insights
Live viral vaccines require safety testing for neurotoxicity. Current monkey-based tests for mumps vaccines are unreliable, prompting development of alternative methods to ensure human safety.
Area of Science:
- Virology
- Vaccinology
- Neuroscience
Background:
- Live, attenuated viral vaccines are derived from wild-type viruses, necessitating pre-clinical neurovirulence safety testing to ensure the absence of residual neurotoxicity.
- Mumps virus, being highly neurotropic, undergoes neurovirulence safety testing in monkeys.
Observation:
- Laboratory studies indicate that current monkey-based neurovirulence testing may not accurately differentiate between mumps virus strains with varying neurovirulence potential in humans.
- Some mumps vaccines deemed neuroattenuated in monkeys later exhibited neurovirulence in humans when administered in large quantities.
Findings:
- Over the last decade, significant efforts have focused on replacing monkey-based neurovirulence safety testing with more informative alternative methods.
- This review examines the current state of mumps vaccine neurovirulence safety testing and evaluates approved and emerging alternative models.
Implications:
- Developing reliable alternative methods for mumps vaccine neurovirulence testing is crucial for enhancing vaccine safety and efficacy.
- Advancements in alternative testing models promise more accurate prediction of vaccine neurovirulence in humans, improving public health outcomes.
Related Concept Videos
Poliomyelitis
Smallpox
Viral Meningitis
Vaccinations
Vaccines

